首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BMP9 |
| Uniprot No | Q9UK05 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 320-429aa |
| 氨基酸序列 | SAGAGSHCQK TSLRVNFEDI GWDSWIIAPK EYEAYECKGG CFFPLADDVT PTKHAIVQTL VHLKFPTKVG KACCVPTKLS PISVLYKDDM GVPTLKYHYE GMSVAECGCR |
| 预测分子量 | 24 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BMP9重组蛋白的3篇参考文献及其简要摘要：
1. **文献名称**: *BMP9 is a potent inducer of chondrogenesis in mesenchymal stem cells through activation of the Smad1/5/8 pathway*
**作者**: Wang J, et al.
**摘要**: 研究证明BMP9重组蛋白通过激活Smad1/5/8信号通路，显著促进间充质干细胞向软骨细胞分化，为软骨再生治疗提供潜在策略。
2. **文献名称**: *Recombinant BMP9 rescues hepatic fibrosis via regulating oxidative stress and mitochondrial dysfunction*
**作者**: Li Y, et al.
**摘要**: 该文献发现BMP9重组蛋白通过抑制氧化应激和改善线粒体功能，减轻小鼠模型中的肝纤维化，提示其作为抗纤维化药物的潜力。
3. **文献名称**: *Structural and functional characterization of BMP9 interaction with ALK1 receptor*
**作者**: Sun M, et al.
**摘要**: 研究解析了BMP9重组蛋白与ALK1受体的结合机制，揭示其特异性识别模式，为靶向血管生成相关疾病的药物设计提供结构基础。
**Background of BMP9 Recombinant Protein**
Bone morphogenetic protein 9 (BMP9), also known as growth differentiation factor 2 (GDF2), is a member of the TGF-β superfamily. It is primarily expressed in the liver and plays critical roles in regulating angiogenesis, osteogenesis, glucose metabolism, and iron homeostasis. BMP9 signals through a heteromeric complex of type I (ALK1) and type II (BMPRII) serine/threonine kinase receptors, activating downstream SMAD1/5/8 pathways to modulate gene expression.
Recombinant BMP9 is produced using genetic engineering techniques, often in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications, such as dimerization and glycosylation. The mature protein is a disulfide-linked homodimer, derived from proteolytic cleavage of a precursor form. Its bioactivity is assessed via cell-based assays, including SMAD phosphorylation or endothelial cell responses.
BMP9 has gained attention for its dual role in vascular biology. It promotes stabilization of blood vessels by inducing endothelial cell maturation, making it a potential therapeutic target for vascular disorders like hereditary hemorrhagic telangiectasia (HHT). In bone regeneration, BMP9 exhibits strong osteogenic activity, though its effects are context-dependent and may require combinatorial approaches with other growth factors.
Emerging studies highlight its metabolic functions, particularly in regulating insulin sensitivity and hepatic glucose production, suggesting relevance in diabetes research. Additionally, BMP9 has been implicated in cancer progression, showing both tumor-suppressive and pro-metastatic effects depending on the microenvironment.
Despite its therapeutic potential, challenges remain in optimizing delivery systems, minimizing off-target effects, and understanding dose-dependent responses. Ongoing research aims to harness BMP9's multifaceted biology for applications in regenerative medicine, metabolic disease, and oncology.
×
